Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Clinical trial NCT04588194 · UNKNOWN

Trial details

NCT number: NCT04588194
Sponsor: David Gomez Almaguer
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Immune Thrombocytopenia Thrombotic Thrombocytopenic Purpura

Start date: 2020-11-01
Primary completion: 2021-11-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.